Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotype-guided Targeted Agents + Pola-RCHP vs Pola-RCHP in Untreated DLBCL
NCT06803693Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Apr 2025
- Primary completion
- Apr 2028
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib, lenalidomide, decitabine in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Started Apr 2025; status: recruiting.
02
Drugs
zanubrutiniblenalidomidedecitabine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06803693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06803693.